# Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

> **NCT02500784** · PHASE2 · WITHDRAWN · sponsor: **Palo Alto Veterans Institute for Research**

## Conditions studied

- Alzheimer's Disease
- Cognitive Dysfunction

## Interventions

- **DRUG:** Formoterol A
- **OTHER:** Formoterol B (placebo)

## Key facts

- **NCT ID:** NCT02500784
- **Lead sponsor:** Palo Alto Veterans Institute for Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01
- **Primary completion:** 2025-04
- **Final completion:** 2025-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding ran out before study started, prior PI left institution.
- **Last updated:** 2020-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500784, "Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02500784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*